Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Haematologica

Volumn 100, Issue 4, 2015, Pages 472-478

  Bardet, Valérie ^a   Wagner Ballon, Orianne ^b   Guy, Julien ^c   Morvan, Céline ^d   Debord, Camille ^a   Trimoreau, Franck ^d   Benayoun, Emmanuel ^b   Chapuis, Nicolas ^a   Freynet, Nicolas ^b   Rossi, Cédric ^c   Mathis, Stéphanie ^a   Gourin, Marie Pierre ^d   Toma, Andréa ^b   Béné, Marie C ^e   Feuillard, Jean ^d   Guérin, Estelle ^d  

^a INSTITUT COCHIN   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d DUPUYTREN UNIVERSITY HOSPITAL   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLAST CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; HEMODILUTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LOW RISK PATIENT; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; OGATA SCORE; PROTEIN EXPRESSION; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD5; ANTIGENS, CD56; ANTIGENS, CD7; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 84926349729     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.112755     Document Type: Article

References (29)

1. Brunning R, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. WHO Classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer. Lyon; 2008. pp. 87-93.
2. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-762.
3. Al-Kali A, Quintás-Cardama A, Luthra R, et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013;88(5):365-369.
4. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122(25):4021-4034.
5. Bowen K, Davis B. Abnormal patterns of expression of CD16 and CD11b by developing neutrophils in the bone marrow of patients with myelodysplastic syndromes. Lab Hematol. 1997;3:292-298.
6. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica. 1998;83(12):1104-1115.
7. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98(4):979-987.
8. Maynadié M, Picard F, Husson B, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood. 2002;100(7):2349-2356.
9. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394-403.
10. Stachurski D, Smith BR, Pozdnyakova O, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res. 2008;32(2):215-224.
11. Van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VHJ, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low-and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008; 111(3):1067-1077.
12. Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer. 2010;116(19): 4549-4563.
13. Della Porta MG, Picone C, Pascutto C, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012;97(8):1209-1217.
14. Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in lowgrade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94(8):1066-1074.
15. Holdrinet RS, von Egmond J, Wessels JM, Haanen C. A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hematol. 1980;8(1):103-107.
16. Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Löwenberg B, Gratama JW. Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination. Cytometry B Clin Cytom. 2009;76(1):18-26.
17. Arroyo JL, Fernández ME, Hernández JM, Orfao A, San Miguel JF, del Cañizo MC. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J. 2004;5(3):227-233.
18. Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005;19(5):776-783.
19. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood. 2008;112(7):2681-2686.
20. Chopra A, Pati H, Mahapatra M, et al. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches. Ann Hematol. 2012; 91(9):1351-1362.
21. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730-1741.
22. Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromesproposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014;28(9):1793-1798.
23. Elghetany MT, Peterson B, MacCallum J, et al. Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res. 1997; 21(9):801-806.
24. Della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006; 20(4): 549-555.
25. Bellos F, Kern W. Flow cytometry in the diagnosis of myelodysplastic syndromes (MDS) and the value of myeloid nuclear differentiation antigen (MNDA). Cytometry B Clin Cytom. 2014 Sept 25. [Epub ahead of print].
26. Arts RJW, Joosten LAB, van der Meer JWM, Netea MG. TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors. J Leukoc Biol. 2013; 93(2):209-215.
27. Rashidi HH, Xu X, Wang H-Y, et al. Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias. Int J Clin Exp Pathol. 2012;5(3):224-230.
28. Lacronique-Gazaille C, Chaury M-P, Le Guyader A, Faucher J-L, Bordessoule D, Feuillard J. A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica. 2007; 92(6):859-860.
29. Chu S-C, Wang T-F, Li C-C, et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res. 2011;35(7):868-873.